Compare Amphastar Pharmaceuticals Inc (AMPH) vs Celestica Inc (CLS) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

CLS trades at $359.85, up 1.43% today, with a bullish technical outlook and strong earnings momentum after beating estimates for three consecutive quarters. The stock shows robust profitability with a 52.45% ROE and 6.95% net margin, supported by positive analyst sentiment and a $440.10 consensus price target. Recent leadership changes and raised revenue guidance to $19 billion highlight growth prospects in AI and cloud infrastructure.

Outlook remains positive driven by AI demand and earnings beats, but high valuation multiples (P/E 43.62) and competitive pressures pose risks. Investors should monitor Q2 2026 results on July 27, 2026, for confirmation of growth trajectory amid margin challenges noted by analysts.